Abstract: Provided herein are influenza hemagglutinin stem polypeptides, nucleic acids encoding said polypeptides, vectors comprising said nucleic acid and pharmaceutical compositions comprising the same, as well as methods of their use, in particular in the prevention and/or treatment of influenza virus infections.

Abstract: The present invention relates to vaccine composition comprising an immunologically effective amount of a viral fusion protein antigen, such as an RSV pre-fusion F protein, and a stabilizing amount of an antiviral compound, and to methods for preparing such vaccine compositions.

Abstract: Provided herein are isolated mutant influenza hemagglutinin polypeptides, methods for providing isolated mutant hemagglutinin polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use, in particular in the detection, prevention and/or treatment of influenza.

Abstract: Provided herein are group 2 influenza hemagglutinin stem polypeptides, nucleic acids encoding said polypeptides, vectors comprising said nucleic acid and pharmaceutical compositions comprising the same, as well as methods of their use, in particular in the prevention and/or treatment of influenza virus infections.

Abstract: Provided herein are influenza hemagglutinin stem polypeptides, nucleic acids encoding said polypeptides, vectors comprising said nucleic acid and pharmaceutical compositions comprising the same, as well as methods of their use, in particular in the prevention and/or treatment of influenza virus infections.

Abstract: Provided herein are influenza hemagglutinin stem polypeptides, nucleic acids encoding said polypeptides, vectors comprising said nucleic acid and pharmaceutical compositions comprising the same, as well as methods of their use, in particular in the prevention and/or treatment of influenza virus infections.

Abstract: The invention provides recombinant influenza A hemagglutinin (HA) polypeptides, comprising an HA1 and a HA2 domain of an influenza A virus HA, and comprising an amino acid sequence wherein: (a) the amino acid at position 355 is W; and (b) the amino acid at position 432 is I and/or the amino acid at position 380 is I; and wherein the numbering of the amino acid positions in the amino acid sequence of the HA polypeptide is according to the numbering of amino acids in the amino acid sequence of HA from a reference H3N2 influenza strain, in particular the reference strain H3N2 A/Aichi/2/68 (SEQ ID NO: 1), immunogenic fragments thereof, nucleic acid molecules encoding said polypeptides or immunogenic fragments, and uses thereof.

Abstract: Provided herein are influenza hemagglutinin stem polypeptides, nucleic acids encoding said polypeptides, vectors comprising said nucleic acid and pharmaceutical compositions comprising the same, as well as methods of their use, in particular in the prevention and/or treatment of influenza virus infections.

Abstract: Binding molecules, such as human monoclonal antibodies, that bind to influenza virus comprising HA of the H3 subtype, such as H3N2, and have a broad neutralizing activity against such influenza virus. Provided are nucleic acid molecules encoding the antibodies, their sequences and compositions comprising the antibodies and methods of identifying or producing the antibodies. The antibodies can be used in the diagnosis, prophylaxis and/or treatment of an influenza virus H3N2 infection. The antibodies may provide cross-subtype protection, such that infections with H3, H7, and/or H10-based influenza subtypes can be prevented and/or treated.

Abstract: Binding molecules, such as human monoclonal antibodies, that bind to influenza virus comprising HA of the H3 subtype, such as H3N2, and have a broad neutralizing activity against such influenza virus. Provided are nucleic acid molecules encoding the antibodies, their sequences and compositions comprising the antibodies and methods of identifying or producing the antibodies. The antibodies can be used in the diagnosis, prophylaxis and/or treatment of an influenza virus H3N2 infection. The antibodies may provide cross-subtype protection, such that infections with H3, H7, and/or H10-based influenza subtypes can be prevented and/or treated.